|Bid||61.23 x 900|
|Ask||61.95 x 800|
|Day's range||60.79 - 62.12|
|52-week range||57.49 - 89.70|
|Beta (5Y monthly)||0.60|
|PE ratio (TTM)||30.78|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||1.16 (1.89%)|
|Ex-dividend date||01 Sept 2022|
|1y target est||72.85|
Shares of Baxter International (NYSE: BAX) were tumbling 8.8% lower as of 11:24 a.m. ET on Thursday after falling as much as 11.8% earlier in the day. The decline came after the healthcare company announced its second-quarter financial results. The company posted Q2 adjusted earnings per share of $0.87, in line with the average estimate of analysts surveyed by Refinitiv.
Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?